Wells Fargo & Company Bicycle Therapeutics PLC Transaction History

Wells Fargo & Company

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$19.9 - $26.25 $238 - $315	12 New	12 $0
Q1 2023 May 12, 2023	BUY	$20.02 - $31.37 $380 - $596	19 New	19 $0
Q2 2022 Aug 12, 2022	BUY	$12.95 - $46.99 $12 - $46	1 New	1 $0
Q1 2022 May 16, 2022	SELL	$40.12 - $59.5 $240,760 - $357,059	-6,001 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$41.7 - $61.14 $4,295 - $6,297	-103 Reduced 1.69%	6,001 $365,000

Q3 2021 Nov 15, 2021	BUY	$27.95 - $44.24 $170,606 - $270,040	6,104 New	6,104 $254,000

30.6M

85.5K

11.6K

Ticker BCYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,676,100
Market Cap $581M
Description
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.